Prostemics Co. Ltd
Ark Solutions Inc. engages in the research and development of products using protein in South Korea, Japan, Mexico, and internationally. It operates through Life and Health Business and Exosome Business divisions. The company offers products using stem cells. The company also provides cosmetics for hospitals and clinics, such as AAPE, a products containing high concentration human cell culture me… Read more
Prostemics Co. Ltd (203690) - Net Assets
Latest net assets as of September 2024: ₩29.24 Billion KRW
Based on the latest financial reports, Prostemics Co. Ltd (203690) has net assets worth ₩29.24 Billion KRW as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩62.86 Billion) and total liabilities (₩33.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩29.24 Billion |
| % of Total Assets | 46.51% |
| Annual Growth Rate | -3.17% |
| 5-Year Change | 7.33% |
| 10-Year Change | N/A |
| Growth Volatility | 76.17 |
Prostemics Co. Ltd - Net Assets Trend (2015–2023)
This chart illustrates how Prostemics Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prostemics Co. Ltd (2015–2023)
The table below shows the annual net assets of Prostemics Co. Ltd from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | ₩30.43 Billion | +209.69% |
| 2022-12-31 | ₩9.83 Billion | -29.45% |
| 2021-12-31 | ₩13.93 Billion | -35.13% |
| 2020-12-31 | ₩21.47 Billion | -24.27% |
| 2019-12-31 | ₩28.35 Billion | -11.08% |
| 2018-12-31 | ₩31.89 Billion | -18.56% |
| 2017-12-31 | ₩39.16 Billion | -12.71% |
| 2016-12-31 | ₩44.86 Billion | +13.91% |
| 2015-12-31 | ₩39.38 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prostemics Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1665096069000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩57.01 Billion | 187.33% |
| Total Equity | ₩30.43 Billion | 100.00% |
Prostemics Co. Ltd Competitors by Market Cap
The table below lists competitors of Prostemics Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
$34.15 Million |
|
Ray Co. Ltd
KQ:228670
|
$34.15 Million |
|
Jaanh CosmeticsInc.
KQ:219550
|
$34.16 Million |
|
Tristar Gold
OTCQB:TSGZF
|
$34.17 Million |
|
CHA Vaccine Institute Co. Ltd.
KQ:261780
|
$34.14 Million |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
$34.13 Million |
|
ONDE S.A. ZY -02
F:0XF
|
$34.11 Million |
|
Singapore Shipping Corporation Limited
F:W1M
|
$34.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prostemics Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 9,826,851,700 to 30,432,343,740, a change of 20,605,492,040 (209.7%).
- Net loss of 24,368,193,000 reduced equity.
- Share repurchases of 13,021,750 reduced equity.
- New share issuances of 14,598,123,500 increased equity.
- Other factors increased equity by 30,388,583,290.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-24.37 Billion | -80.07% |
| Share Repurchases | ₩13.02 Million | -0.04% |
| Share Issuances | ₩14.60 Billion | +47.97% |
| Other Changes | ₩30.39 Billion | +99.86% |
| Total Change | ₩- | 209.69% |
Book Value vs Market Value Analysis
This analysis compares Prostemics Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.46x to 1.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩993.15 | ₩4425.00 | x |
| 2017-12-31 | ₩883.04 | ₩4425.00 | x |
| 2018-12-31 | ₩715.74 | ₩4425.00 | x |
| 2019-12-31 | ₩632.13 | ₩4425.00 | x |
| 2020-12-31 | ₩477.88 | ₩4425.00 | x |
| 2021-12-31 | ₩309.98 | ₩4425.00 | x |
| 2022-12-31 | ₩217.97 | ₩4425.00 | x |
| 2023-12-31 | ₩2738.73 | ₩4425.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prostemics Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.41%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 2.54x
- Recent ROE (-80.07%) is below the historical average (-30.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -21.63% | -57.41% | 0.34x | 1.10x | ₩-12.45 Billion |
| 2016 | 9.62% | 30.45% | 0.30x | 1.05x | ₩-172.64 Million |
| 2017 | -8.06% | -48.10% | 0.16x | 1.04x | ₩-7.07 Billion |
| 2018 | -19.75% | -133.46% | 0.14x | 1.04x | ₩-9.49 Billion |
| 2019 | -11.23% | -44.66% | 0.22x | 1.12x | ₩-6.02 Billion |
| 2020 | -33.83% | -35.05% | 0.34x | 2.80x | ₩-9.41 Billion |
| 2021 | -51.99% | -22.26% | 0.61x | 3.82x | ₩-8.63 Billion |
| 2022 | -56.59% | -20.92% | 0.52x | 5.24x | ₩-6.54 Billion |
| 2023 | -80.07% | -65.41% | 0.48x | 2.54x | ₩-27.41 Billion |
Industry Comparison
This section compares Prostemics Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prostemics Co. Ltd (203690) | ₩29.24 Billion | -21.63% | 1.15x | $34.15 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |